1. Home
  2. MAIA vs MYO Comparison

MAIA vs MYO Comparison

Compare MAIA & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

SELL

Current Price

$1.01

Market Cap

69.2M

Sector

Health Care

ML Signal

SELL

Logo Myomo Inc.

MYO

Myomo Inc.

SELL

Current Price

$1.04

Market Cap

63.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MAIA
MYO
Founded
2018
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.2M
63.8M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
MAIA
MYO
Price
$1.01
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
★ $12.00
$4.64
AVG Volume (30 Days)
★ 246.6K
216.5K
Earning Date
11-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 33.33
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,000,000,000.00
Revenue This Year
N/A
$13.25
Revenue Next Year
N/A
$10.45
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 40814.79
52 Week Low
$0.87
$0.61
52 Week High
$3.19
$1.89

Technical Indicators

Market Signals
Indicator
MAIA
MYO
Relative Strength Index (RSI) 38.89 36.27
Support Level N/A $0.93
Resistance Level $1.48 $1.22
Average True Range (ATR) 0.06 0.11
MACD -0.00 -0.01
Stochastic Oscillator 23.11 2.27

Price Performance

Historical Comparison
MAIA
MYO

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

Share on Social Networks: